Item 5. Other Information

Rule 10b5-1 Director and Officer Trading Arrangements

During the three months ended October 27, 2023, certain of our officers and directors adopted “Rule 10b5-1 trading arrangements,” intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act as follows.

On September 20, 2023, Brett Wall, Executive Vice President and President Neuroscience Portfolio, adopted a Rule 10b5-1 trading plan. Mr. Wall’s trading plan provides for the sale of 4,997 shares of the Company’s common stock at market on December 19, 2023 prior to the plan's December 22, 2023 termination date.